Table 3.
Comparisons on metabolites in the blood plasma among control and cancer groups.
| Metabolites | Control (Groups 1, 2) | Cancer (Groups 3, 4) | p | ||
|---|---|---|---|---|---|
| M + SD (ranges) |
1-Healthy n = 4 |
2-Chronic Disease n = 11 |
3-Cancer n = 5 |
4-Advanced n = 10 |
|
| Homocysteine (µmol/L) | 4.5 ± 1.8 (3.1–7) |
5.1 ± 1.0 (4.2–7.2) |
8.6 ± 3.8 (5.8–14) |
9.1 ± 4.2 (4–17) |
0.014 |
| Posthoc | <4 (p = 0.023) | <3 (p = 0.028)<4 (p = 0.019) | |||
| SAM (nmol/L) | 85 ± 24 (70–122) |
89 ± 17 (63–120) |
129 ± 61 (77–233) |
102± 21 (67–134) |
0.12 |
| SAH (nmol/L) | 25 ± 14 (11–43) |
23 ± 7.2 (12–38) |
52 ± 51 (23–142) |
29 + 13 (16–56) |
0.25 |
| Posthoc | <3 (p = 0.041) | ||||
| SAM/SAH Ratio | 4.1 ± 1.9 (1.7–6.3) |
4.2 ± 1.1 (2.8–6.3) |
3.2 ± 1.1 (1.6–4.6) |
3.9 ± 1.1 (0–5.2) |
0.56 |
| ADMA (nmol/L) | 573 ± 198 (393–849) |
519 ± 110 (278–720) |
666 ± 223 (472–917) |
557 ± 110 (406–754) |
0.77 |
| SDMA (nmol/L) | 488 ± 130 (324–642) |
466 ± 78 (340–589) |
885 ± 671 (401–2050) |
516 ± 109 (425–778) |
0.44 |
| Methionine (nmol/L) | 37 ± 10 (27–51) |
30 ± 7.3 (20–46) |
32 ± 4.8 (26–39) |
26 ± 6.2( 18–38) |
0.14 |
| Posthoc | <3 (p = 0.041) | ||||
| MMA (nmol/L) | 249 ± 48 (185–301) |
285 ± 229 (178–972) |
359 ± 72 (304–480) |
274 ± 97 (186–521) |
0.025 |
| Posthoc | <3 (p = 0.02) | <3 (p = 0.013) | |||
| Cystathionine (nmol/L) | 423 ± 267 (227–796) |
243 ± 147 (107–600) |
470 ± 221 (193–692) |
244 ± 102 (149–502) |
0.043 |
| Posthoc | <3 (p = 0.041) | <3 (p = 0.043) | |||
| Betaine (nmol/L) | 71 ± 18 (48–89) |
63 ± 20 (38–111) |
61 ± 24 (37–96) |
53 ± 11 (36–67) |
0.45 |
| Vitamin B-6 (nmol/L) | 50 ± 16 (29–67) |
60 ± 42 (14–155) |
64 ± 52 (5.3–128) |
46 ± 24 (20–88) |
0.95 |
| 5-MTHF (nmol/L) | 30 ± 10 (18–43) |
48 ± 19 (30–97) |
36 ± 5.3 (32–45) |
36 ± 16 (18–78) |
0.063 |
| Posthoc | <2 (p = 0.045) | ||||
| Choline (nmol/L) | 12 ± 5.7 (7.9–21) |
9.7 ± 2.8 (5.7–16) |
14 ± 7.5 (8–27) |
10 ± 3.1 (6.9–18) |
0.50 |
Nonparametric test, Posthoc by Wilcoxon test; 4 groups: inflammation status indicated by chronic health diseases (Group 2) or advanced cancer stage (Group 4); SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; ADMA: Asymmetric dimethylarginine; SDMA: Symmetric dimethylarginine; MMA: Methylmalonic acid; 5-MTFH: 5-methyltetrahydrofolate or methyl-folate.